Patrick Machado is 10% Owner at Urovant Sciences Ltd. (UROV). They have made 30 open-market trades across 5 companies since 2016, most recently 2026-06-30.
CIK 0001311210
30 open-market purchases totalling $205.7M since 2016, never a sale. Across 30 scored buys the stock is up 6.3% at ninety days, and 2.9 points ahead of the S&P over the same stretch.
30 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 47% | 70% | 70% |
| Avg Move | +0.3% | +4.4% | +6.3% |
| Alpha | -0.4% | +1.4% | +2.9% |
| Scored | 30 | 30 | 30 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADVM | BUY | 2021-03-24 | 2021-03-24 | $9.92 | $99K | +1.7% | -2.3% | -62.8% |
| ADVM | BUY | 2021-01-15 | 2021-01-19 | $11.52 | $115K | -7.0% | -3.2% | -32.4% |
| UROV | BUY | 2019-06-18 | 2019-06-19 | $8.21 | $55K | -5.1% | +3.9% | +15.5% |
| UROV | BUY | 2019-06-17 | 2019-06-19 | $8.53 | $56K | -5.1% | +3.9% | +15.5% |
| UROV | BUY | 2019-06-17 | 2019-06-19 | $8.31 | $303K | -5.1% | +3.9% | +15.5% |
| UROV | BUY | 2019-06-14 | 2019-06-14 | $7.91 | $57K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-13 | 2019-06-14 | $7.95 | $59K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-12 | 2019-06-14 | $8.06 | $355K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-12 | 2019-06-14 | $8.30 | $62K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-11 | 2019-06-11 | $8.58 | $62K | -6.7% | +6.1% | +20.7% |
| UROV | BUY | 2019-06-10 | 2019-06-11 | $8.35 | $63K | -6.7% | +6.1% | +20.7% |
| UROV | BUY | 2019-06-07 | 2019-06-11 | $8.30 | $292K | -6.7% | +6.1% | +20.7% |
| UROV | BUY | 2019-06-07 | 2019-06-11 | $7.97 | $53K | -6.7% | +6.1% | +20.7% |
| UROV | BUY | 2019-06-06 | 2019-06-06 | $8.00 | $57K | +4.5% | +2.1% | +13.9% |
| UROV | BUY | 2019-06-05 | 2019-06-06 | $8.02 | $52K | +4.5% | +2.1% | +13.9% |
| UROV | BUY | 2019-06-04 | 2019-06-06 | $7.59 | $57K | +4.5% | +2.1% | +13.9% |
| MYOV | BUY | 2019-06-04 | 2019-06-06 | $8.25 | $40.0M | -2.7% | -12.4% | -14.1% |
| UROV | BUY | 2019-06-04 | 2019-06-06 | $7.90 | $218K | +4.5% | +2.1% | +13.9% |
| UROV | BUY | 2019-05-30 | 2019-06-03 | $7.87 | $194K | +0.0% | +2.4% | +19.1% |
| UROV | BUY | 2019-05-29 | 2019-05-29 | $7.55 | $52K | +7.2% | -0.4% | -4.7% |
| UROV | BUY | 2019-05-24 | 2019-05-29 | $7.62 | $221K | +7.2% | -0.4% | -4.7% |
| UROV | BUY | 2019-05-21 | 2019-05-23 | $8.32 | $248K | +3.6% | +4.3% | +1.6% |
| UROV | BUY | 2019-05-20 | 2019-05-20 | $7.98 | $66K | -6.8% | -0.8% | -4.4% |
| UROV | BUY | 2019-05-16 | 2019-05-20 | $7.54 | $326K | -6.8% | -0.8% | -4.4% |
| AXON | BUY | 2019-03-18 | 2019-03-19 | $1.50 | $20.0M | +4.1% | +14.5% | +30.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| ECYT | 7,050 | $169K |
| XENE | 2,645 | $89K |
| SLRN | 14,675 | $33K |
| ALMS | 3,553 | $22K |
| Total | $42.8B |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.